PipelineReview.com4h
Ethris and Lonza Collaborate to Develop Spray-Dried mRNA Vaccines for Respiratory Disease Prevention
MUNICH, Germany & BASEL, Switzerland I April 07, 2025 I Ethris, a clinical-stage biotechnology company pioneering next-generation RNA therapeutics and ...
PipelineReview.com4h
ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate
SOUTH SAN FRANCISCO, CA, USA I April 07, 2025 I ALX Oncology Holdings Inc., (“ALX Oncology” or the “Company”) (Nasdaq: ALXO), a clinical-stage biotechnology ...
PipelineReview.com4h
Teva and Samsung Bioepis Announce Biosimilar EPYSQLI® (eculizumab-aagh) Injection Now Available in the United States
PARSIPPANY, NJ, USA and INCHEON, Korea I April 07, 2025 I Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), ...
PipelineReview.com13h
ABL Bio Announces Grabody-B Brain Delivery Platform License Agreement with GSK to Develop Novel Medicines for Neurodegenerative Diseases
ABL Bio and GSK enter into a multi-program agreement to develop novel medicines for neurodegenerative diseases ...
PipelineReview.com3d
Imfinzi-based perioperative regimen approved in the EU for resectable non-small cell lung cancer
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone Professor Martin Reck, Head of the ...
PipelineReview.com3d
Enlivex Announces the Dosing of the First Patient in a Phase I Trial Evaluating Allocetra in Patients with TMJ Osteoarthritis
NESS-ZIONA, Israel I April 03, 2025 I Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company” or “Enlivex”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the ...
PipelineReview.com3d
Auron Presents New Preclinical Data for AUTX-703 in Small Cell Lung Cancer (SCLC)
AUTX-703, a novel and potent oral KAT2A and KAT2B protein degrader, inhibits growth and induces profound, persistent cell state differentiation in SCLC models NEWTON, MA, USA I April 03, 2025 I Auron ...
PipelineReview.com3d
Uplizna® (inebilizumab-cdon) is now the first and only FDA-approved treatment for IgG4-related disease
Advances Amgen’s Leadership in CD19 Directed, B-Cell Depletion Therapies for Serious Autoimmune Diseases Including NMOSD, IgG4-RD and gMG THOUSAND OAKS, CA, USA I April 3, 2025 I Amgen (NASDAQ:AMGN) ...
PipelineReview.com3d
Genentech and Roche Present Novel Therapeutic and Diagnostic Advancements in Alzheimer’s at AD/PD 2025
– New trontinemab data continue to support rapid and deep, dose-dependent reduction of amyloid plaques in Phase Ib/IIa Brainshuttle™ AD study – – Data on the Elecsys ® pTau181 plasma test demonstrate ...
PipelineReview.com3d
Akamis Bio Announces Enrollment of First Patient in Phase 1b FORTRESS Trial of NG-350A in Patients with Locally Advanced Rectal Cancer
NG-350A is a next generation, systemically administered immunotherapy designed to drive intratumoral expression of a CD40 agonist monoclonal antibody in both primary and metastatic tumor sites ...
PipelineReview.com3d
Meitheal Pharmaceuticals Announces Approval and Launch of Liraglutide Injection in the United States
CHICAGO, IL, USA I April 03, 2025 I Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated biopharmaceutical company based in Chicago focused on the development and commercialization of ...
PipelineReview.com3d
Epicrispr Biotechnologies Announces FDA Clearance of IND Application for EPI-321, A First-in-Class Epigenetic Therapy for FSHD
– U.S. IND clearance follows recent approval of CTA for EPI-321 in facioscapulohumeral muscular dystrophy (FSHD) in New Zealand SOUTH SAN FRANCISCO, CA, USA I April 03, 2025 I Epicrispr ...